| A1 Case Management | |
|
112 W Chisholm St Alpena MI 49707-2446 | |
| (989) 340-1645 | |
| Not Available |
| Full Name | A1 Case Management |
|---|---|
| Speciality | Case Management |
| Location | 112 W Chisholm St, Alpena, Michigan |
| Authorized Official Name and Position | Katherine Witkowski (FOUNDER) |
| Authorized Official Contact | 9893401645 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| A1 Case Management 350 N 2nd Ave Unit 678 Alpena MI 49707-6229 Ph: (989) 340-1645 | A1 Case Management 112 W Chisholm St Alpena MI 49707-2446 Ph: (989) 340-1645 |
| NPI Number | 1679190151 |
|---|---|
| Provider Enumeration Date | 06/30/2020 |
| Last Update Date | 07/17/2020 |
| Certification Date | 07/17/2020 |
| Medicare PECOS PAC ID | 5092130641 |
|---|---|
| Medicare Enrollment ID | O20200730001135 |
News Archive
Stanley Hazen, M.D., Ph.D., was recently honored with an inaugural Top 10 Clinical Research Achievement Award from an organization comprised of the nation's most acclaimed academic medical centers and other groups, in recognition of Dr. Hazen's Nature article, "Gut flora dependent metabolism of dietary phosphatidylcholine contributes to cardiovascular disease."
The 5th International Conference on Polyphenols and Health will bring together over 700 researchers from around the world to discuss the latest findings on the polyphenolic components of food and their role in disease prevention and health promotion.
Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.
Experts examining patterns in ultrasound images can more accurately classify ovarian tumors as benign or malignant than can pre-surgical blood tests, according to a study published online in the Nov. 13 Journal of the National Cancer Institute.
An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679190151 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 104100000X | Social Worker | (* (Not Available)) | Secondary |
| 251B00000X | Case Management | (* (Not Available)) | Primary |
| Provider Name | Danica Dumsch |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1720419252 PECOS PAC ID: 7810287745 Enrollment ID: I20160606002541 |
News Archive
Stanley Hazen, M.D., Ph.D., was recently honored with an inaugural Top 10 Clinical Research Achievement Award from an organization comprised of the nation's most acclaimed academic medical centers and other groups, in recognition of Dr. Hazen's Nature article, "Gut flora dependent metabolism of dietary phosphatidylcholine contributes to cardiovascular disease."
The 5th International Conference on Polyphenols and Health will bring together over 700 researchers from around the world to discuss the latest findings on the polyphenolic components of food and their role in disease prevention and health promotion.
Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.
Experts examining patterns in ultrasound images can more accurately classify ovarian tumors as benign or malignant than can pre-surgical blood tests, according to a study published online in the Nov. 13 Journal of the National Cancer Institute.
An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.
› Verified 1 days ago
| Provider Name | Sarah Hamilton |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1982122081 PECOS PAC ID: 0345672010 Enrollment ID: I20191118003237 |
News Archive
Stanley Hazen, M.D., Ph.D., was recently honored with an inaugural Top 10 Clinical Research Achievement Award from an organization comprised of the nation's most acclaimed academic medical centers and other groups, in recognition of Dr. Hazen's Nature article, "Gut flora dependent metabolism of dietary phosphatidylcholine contributes to cardiovascular disease."
The 5th International Conference on Polyphenols and Health will bring together over 700 researchers from around the world to discuss the latest findings on the polyphenolic components of food and their role in disease prevention and health promotion.
Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.
Experts examining patterns in ultrasound images can more accurately classify ovarian tumors as benign or malignant than can pre-surgical blood tests, according to a study published online in the Nov. 13 Journal of the National Cancer Institute.
An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.
› Verified 1 days ago
News Archive
Stanley Hazen, M.D., Ph.D., was recently honored with an inaugural Top 10 Clinical Research Achievement Award from an organization comprised of the nation's most acclaimed academic medical centers and other groups, in recognition of Dr. Hazen's Nature article, "Gut flora dependent metabolism of dietary phosphatidylcholine contributes to cardiovascular disease."
The 5th International Conference on Polyphenols and Health will bring together over 700 researchers from around the world to discuss the latest findings on the polyphenolic components of food and their role in disease prevention and health promotion.
Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.
Experts examining patterns in ultrasound images can more accurately classify ovarian tumors as benign or malignant than can pre-surgical blood tests, according to a study published online in the Nov. 13 Journal of the National Cancer Institute.
An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.
› Verified 1 days ago
Sunrise Centre, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 630 Walnut St, Alpena, MI 49707 Phone: 989-356-6649 Fax: 989-356-3559 | |
Northern Sky Therapeutic Services, Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 150 S Ripley Blvd, Alpena, MI 49707 Phone: 989-884-0066 | |
Alcona Health Center-alpena Services Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1185 Us Highway 23 N, Alpena, MI 49707 Phone: 989-356-4049 Fax: 989-358-3712 | |
Thunder Bay Junior High School Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3500 S Third Ave, Alpena, MI 49707 Phone: 989-736-8157 | |
Ahc Lincoln School Wildcat Health Extension Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 309 W Lake St, Alpena, MI 49707 Phone: 989-358-3998 | |
Northeast Michigan Community Mental Health Authority Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 400 Johnson St, Alpena, MI 49707 Phone: 989-356-2161 Fax: 989-354-5898 | |
Ahc-alpena High School Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3303 S Third Ave, Alpena, MI 49707 Phone: 989-358-5200 |